Key Highlights
● Iovance shares climbed sharply in extended trading.
● The move came ahead of upcoming lung-cancer data.
● Its approved product currently treats advanced melanoma.
● The company uses tumor-infiltrating lymphocyte cell therapy.
Iovance Biotherapeutics (NASDAQ:IOVA) jumped after the bell, with the cell-therapy developer's shares climbing sharply in extended trading ahead of upcoming lung-cancer data. The move came after the regular session closed, putting Iovance among the most-talked-about small-cap names going into the next session.
Further details on the timing and content of the data were not available in the reports reviewed, and after-hours moves can reverse once regular trading resumes.
Why Lung Cancer Matters
Iovance's lead product is approved in the United States for advanced melanoma, a form of skin cancer. Expanding into lung cancer, one of the most common and deadly cancers, would open a far larger market for its technology.
Investors often bid up biotech shares ahead of key data releases, betting on positive results, which can lead to sharp swings in both directions once the data is published, depending on whether it meets expectations.
What Iovance Does
Iovance develops therapies based on tumor-infiltrating lymphocytes, immune cells taken from a patient's own tumor, grown into large numbers in a laboratory and then infused back into the patient to attack the cancer.
The approach is complex and individualized, requiring specialized manufacturing for each patient, and Iovance has been working to build out treatment centers and production capacity while testing the technology in other solid tumors, including lung cancer.






Please wait processing your request...